121808-62-6
Chemical Structure
Pidotimod
- CAS No.: 121808-62-6
- Formula:C9H12N2O4S
- Molecular Weight:244.27
IUPAC Name: (R)-3-((S)-5-oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acid
InChIKey: UUTKICFRNVKFRG-WDSKDSINSA-N
SMILES: O=C([C@H]1N(C([C@H](CC2)NC2=O)=O)CSC1)O
Biological Activity: Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pidotimod | 99.96% | Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pidotimod (Standard) | ≥98% | Pidotimod (Standard) is the analytical standard of Pidotimod. This product is intended for research and analytical applications. Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ashok Mahashur, et al. Pidotimod: In-depth review of current evidence. Lung India [Content Brief]
- [2]. Ning Zhao, et al. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther. 2019 Oct;17(10):803-818. [Content Brief]
Keywords
